Theravance Biopharma, Inc. (TBPH) insider trading

By person

35 insiders · 85 transactions

28.0×

Rick E Winningham holds 28.0 times base salary in stock. $29.42M of shares against $1.05M in salary for 2025.

Salary from the company's own proxy. The shares are what Rick E Winningham last reported holding, valued at $17.03, the price Ordinary Shares was last bought or sold at on the open market here, on 15 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Eli Samaha

10% owner

$20.92M (3)

$5.79M (3)

+$15.12M

9,174,453

$156.28M

+30.8%

Bradford J Shafer

EVP, Gen. Counsel, Secretary

—

$2.71M (8)

−$2.71M

277,831

$4.73M

+37.5%

Rhonda Farnum

SVP, Comm & Medical Affairs

—

$2.12M (27) scheduled

−$2.12M

$0.00

−100.0%

Eran Broshy

Director

—

$1.66M (5) scheduled

−$1.66M

44,703

$761.48K

−17.2%

Renee D Gala

SVP, Chief Financial Officer

—

$1.41M (4)

−$1.41M

157,657

$2.69M

−32.8%

Brett K Haumann

Chief Medical Officer

—

$898.21K (3)

−$898.21K

242,499

$4.13M

+28.8%

Burton G Malkiel

Director

$760.21K (3)

—

+$760.21K

115,589

$1.97M

+335.0%

Philip D Worboys

SVP, Research & Transl Science

—

$743.06K (4)

−$743.06K

330,752

$5.63M

+82.3%

Andrew A. Hindman

SVP, Chief Financial Officer

—

$716.24K (1)

−$716.24K

384,714

$6.55M

+5,951%

Richard A Graham

SVP, Research & Development

—

$592.92K (14)

−$592.92K

314,915

$5.36M

+182.8%

Rick E Winningham

Chief Executive Officer

$245.00K (1)

$559.50K (1)

−$314.50K

23,400

$398.60K

−97.4%

Sharathchandra S Hegde

SVP, Research

—

$223.17K (2)

−$223.17K

259,900

$4.43M

+49.8%

Henrietta Fore

Director

$143.93K (1)

—

+$143.93K

24,000

$408.82K

+100.0%

Frank Pasqualone

SVP, Chief Business Officer

$105.36K (1)

—

+$105.36K

429,783

$7.32M

+90.8%

George M Whitesides

Director

$98.76K (1)

—

+$98.76K

249,076

$4.24M

+9.7%

Donal O'Connor

Director

—

$81.83K (2)

−$81.83K

$0.00

−100.0%

Vijay Sabesan

SVP, Technical Operations

—

$21.60K (1)

−$21.60K

235,524

$4.01M

+49.0%

Kenneth R Pitzer

SVP, Prod Strat & Comm Plng

—

380,123

$6.48M

+130.2%

Junning Lee

Sr. VP, Technical Operations

—

234,071

$3.99M

−5.4%

Ann Brady

President, Tbil

—

110,319

$1.88M

+42.6%

Shehnaaz Suliman

SVP, Corp Dev & Strategy

—

97,198

$1.66M

+5,515%

Robert V Gunderson JR

Director

—

78,940

$1.34M

+97.8%

William D Young

Director

—

78,010

$1.33M

+167.9%

Susan Molineaux

Director

—

51,034

$869.32K

+325.3%

Peter S Ringrose

Director

—

37,999

$647.28K

+146.3%

Jeremy T Grant

Director

—

32,954

$561.35K

—

Dean J Mitchell

Director

—

$0.00

−100.0%

Susannah Gray

Director

—

$0.00

—

GSK plc entity

Former 10% Owner

—

$0.00

−100.0%

Aziz Sawaf

SVP & Chief Financial Officer

—

$0.00

−100.0%

Aine Miller

SVP, Dev & Head of Ire Office

—

$0.00

−100.0%

Brett A. Grimaud

SVP, Gen Counsel and Secretary

—

$0.00

−100.0%

Alsup Laurie Smaldone

Director

—

$0.00

—

Deepika Pakianathan

Director

—

$0.00

—

Weiss Asset Management LP entity

Former 10% Owner

—

$0.00

−100.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Theravance Biopharma, Inc.

What the insiders did Net buying

By person